Supplemental Figures
Figure S1 is related to Figure 1 . Figure S2 is related to Figure 2 . Figure S3 is related to Figure 3 . Figure S4 is related to Figure 5 . Figure S5 is related to Figure 6 . Figure S6 is related to Figure 7 . (A) Microscopic H&E analysis of 5 study cohort genotypes at indicated time points reveals cooperation between Pten and Phlpp1. Degree of malignancy for low grade- (lg) or high grade-(hg) PIN is shown for those ages and genotypes where at least 50% penetrance of PIN was found. Cases with adenocarcinoma (ca) are indicated (see Monoclonal antibodies used were p53 (Clone IMX25, Accurate Chemical Corp), Pten (Clone 6H2.1, Millipore), beta-Actin (A5441, Sigma) and gamma-Tubulin (T6199, Sigma). Western blots were developed using the enhanced chemiluminescence detection reagent (Millipore) and the Odyssey Infrared Imaging System (Li-Cor).
Supplemental Experimental Procedures
Quantification of densitometry was performed using ImageJ 1.38X (NIH) software.
Immunohistochemistry (IHC), Quantifications, senescence associated β-gal staining, and Immunofluorescence (IF)
Tissues were fixed in 10% formalin and embedded in paraffin. Sections were processed with H&E reagents or stained for phopho-Akt (Ser 473 , IHC-specific, #4060, Cell signalling), PTEN/MMAC1 Ab-2 (#RB-072-PO, NeoMarkers), PHLPP1 (IHC-00382, 15 Bethyl Lab, 1:700 dilution), Ki-67 (VP-K451, Vector Labs), p53 (FL-393, Santa Cruz), p63 (4A4, Santa Cruz), Cleaved Caspase 3 (#9661, Cell Signaling), CD3 (#A0452, Dako), or Cytokeratin 5 (AF-138, Covance) using Discovery XT processor (Ventana Medical Systems) as previously described (Trotman et al., 2003) . The slides were processed using citrate buffer (10mM, ph=6.0) based antigen retrieval, and the avidinbiotin peroxidase IHC method. Quantification of malignancy was done as follows: for Ki-67 staining cells were counted after imaging with a Zeiss Axioplan microscope (40x objective). Numbers of mice (n), histology sections/ animal (s), and cells counted/ section (c) were: WT, n=3, s=4, c=630. Pten +/-, n=3, s=6, c=907. Phlpp -/-, n=3, s=6, c=1429. Pten +/-; Phlpp -/-, n=5, s=9, c=1976. Pten +/-; Phlpp +/-, n=6, s=8, c=1592.
For apoptosis (cleaved caspase 3) and immune response (Cd3) between 500-1500 cells total were counted on 4 sections per genotype and age. For lesion size, straight lines forming the maximal diameter of a neoplasia were drawn using the measurement tool of the SPOT microscopy imaging software (www.diaginc.com) on 4 sections per genotype and age. Statistical analysis was performed using the one-tailed student's ttest. Frozen sections were fixed in 0.5% glutaraldehyde, followed by wash with PBS, then PBS/MgCl 2 (pH 5.5). Fresh X-gal staining solution (Roche) was applied, and the slides were incubated at 37˚C. Then the slides were washed with PBS twice, fixed with 4% formalin, and counter-stained with eosin.
For IF, cells were seeded on glass cover slips in 24-well plates and fixed with 4% para-fomaldehyde for 10 min followed by 50 mM NH 4 Cl for 10 min, 0.5% Triton X-100 for 5 min, and PBS (3 times wash), 10% goat serum (30 min) and primary antibodies hemagglutinin (HA) (Clone 12CA5, CSHL monoclonal antibody core) and phopho-Akt (Ser 473 , IHC-specific, #4060, Cell Signaling), were applied for 5 hours at 4 degrees or as indicated by the manufacturer. 
Cells, Infection and Treatment
MEFs were isolated as previously described (Trotman et al., 2006) For soft agar assay, primary MEFs and selected MEFs were suspended in medium containing 0.3% agar onto solidified 0.6% agar at a concentration of 1 x 10 4 cells per well of a six-well plate, and the number of colonies was assessed after 21 days. For Akt inhibition, cells were treated with 5uM AKT inhibitor XIII (Calbiochem, Cat# 124017) for 6 hours and harvested for western blot analysis and viability assay. To assess cell viability, cells were stained with Propidium iodide (Millipore) and PI positive cells were measured by flow cytometry using the Guava easyCyte 8HTsystem (Millipore). For mTOR inhibition, cells were treated with 100 nM rapamycin (LC Laboratories) for 24 hours and harvested for western blot analysis. NIH3T3 and MEFs were treated with UV at the dose of 50 J/m at 245nm and harvested 24 hours post treatment. To determine protein half-life, 1 x 10 6 cells were seeded on 10cm dishes, treated with 100 mg/ml cycloheximide (Calbiochem) and harvested at the indicated times for western blot analysis. Pten/ Trp53 deleted MEFs were previsously described (Chen et al., 2005) .
HCT116 PTEN +/+ and HCT116 PTEN -/-(KO22) cells were a kind gift from Dr. Todd Waldman (Kim et al., 2006) . Tsc1 -/-MEFs were a kind gift from Dr. David Kwiatkowski (Kwiatkowski et al. 2002) .
RNA expression array analysis
RNA quality was assessed on an Agilent 2100 Bioanalyzer, RNA 6000 Pico Series II Chips (Agilent, Palo Alto, CA, USA). Samples with a RIN score 2.0 or greater were passed, and quantity was determined by Nanodrop ND-1000 (Nanodrop Technologies, Wilmington, DE). Total RNA was amplified by a modified Eberwine Technique, and aRNA converted to cDNA using the WT Expression kit (Ambion, Austin, TX, see Van
Gelder RN et al. Proc Natl Acad Sci USA, 1990 , 87: 1663 -1667 . Size distribution of aRNA and cDNA was assessed and 3' bias was performed on all samples and products using the Agilent 2100 Bioanalyzer RNA 6000 Nano Series II Chips (Agilent, Palo Alto, CA, USA). The cDNA was then fragmented and terminally labeled with biotin, using the Affymetrix GeneChip WT Terminal Labeling kit (Affymetrix, Santa Clara, CA). Samples were prepared for hybridization, hybridized, washed, and scanned according to the manufacturer's instructions on Mouse Gene ST 1.0 GeneChips (Affymetrix, Santa Clara, CA). Affymetrix Expression Console QC metrics were used to pass the image data.
Quantitative real time PCR
RNA was isolated from tissue (AllPrep) or cells (Trizol method, Ambion), and cDNA was produced from 2ug of RNA using the SuperScript III system with oligo dT primers (Invitrogen) as suggested by the manufacturer. Quantitative real-time PCR was performed on the LightCycler 480 Real-Time PCR System using the SYBR Green I Master (Roche) and the following amplification protocol: 5 min at 95°C, 40 cycles (15 sec at 94°C -10 sec at 60°C -10 sec at 72°C) followed by determination/confirmation of amplicon melting temperature. Reactions were performed in triplicates, 3 primer pairs for each gene were confirmed to yield a single amplicon band by 2% agarose gel 18 the following genotypes and ages: 6 Pten +/-; Phlpp1 -/animals (2-11 months), 1 Phlpp1 -/animal (6 months), 2 wt animals (4 and 8 months), 1 Pten +/-; Phlpp1 +/animal (10 months), 1 Pten +/-; animal (8 months), as well as from low passage primary Phlpp1 -/-MEFs, and cDNA was synthesized as described above. Full-length p53 transcripts were amplified to yield three Sanger sequencing compatible fragments using three primer pairs: pair 1, Fwd1 (5'-TTTCCCCTC CCACGTGCTCACCCTGG -3'), Rev1 (5'-CGGAGCAGCGCTCATGGTGGGGGCAGC G -3'), pair 2, Fwd2 (5'-CCGCGCCAT GGCCATCTACAAG -3'), Rev2 (5'-CTCTAAGGCCTCATTCAGCTCCCGG -3'), pair 3, Fwd3 (5'-CCGCGGGCGTAAACGCTTCGAGATG -3'), Rev3 (5'-GGGAGACAG GGTGGGGGGTGG -3') with a High-Fidelity PCR kit (Invitrogen).
The PCR products were examined on 2% agarose gel and then purified using a PCR purification kit (Qiagen). PCR products were cloned into the pCR4-TOPO vector using the TOPO TA Cloning Kit for Sequencing (Invitrogen) as suggested by the manufacturer. 30 clones were picked for each prostate sample, grown and mini-prepped (Qiagen) and sent for sequencing using M13 Forward and M13 Reverse primers.
Sequence data was collected on an ABI3730 automated sequencer. All sequence files were analyzed using DNA Strider 1.4f2.
Identification of function-inactivating missense mutations was as follows: protein missense mutations from mouse were aligned with the human p53 protein sequence to identify corresponding conserved residues. For the following steps the International Agency for Research on Cancer (IARC) TP53 database was used (http://www-p53.iarc.fr): conserved mutations were analyzed for 1) their identification in human cancer tissue, and 2) loss of more than 80% transactivation activity on p21 based on the published database (Kato S. et al., Proc Natl Acad Sci USA 2003,100, 8424-8429) that used a reporter assay in yeast (data displayed on IARC TP53 database for each mutation).
Short hairpin and small interfering RNA
The short hairpin RNA against mouse Phlpp1 (TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCCAGAGAAACAGTTAATGATAATA 20 GTGAAGCCACAGATGTATTATCATTAACTGTTTCTCTGTTGCCTACTGCCTCGG) was generated on the basis of BIOPREDsi algorithms (Huesken D et al. Nat Biotechnol 2005; 23, 995-1001.) and synthesized as a 110 bp oligo (Sigma), cloned into LMP (Dickins RA et al. Nat Genet. 2005; 37, 1289 -1295 and verified by sequencing. NIH3T3 cells were infected with candidate shRNAs to determine knockdown efficiency by western blotting, and the most effective hairpins were used in all experiments. Primary MEFs were infected and selected as described above. shPten, shLuciferase and shp53 were kind gifts from Dr. Scott Lowe. siRNA Smart-pool (Dharmacon) against mouse Phlpp2 were transfected to MEFs at the final concentration of 50 nM using Dharmafect 1(Dharmacon) following the manufacturer's instruction.
Relapse free survival and scoring of TMAs
Disease recurrence after radical prostatectomy was defined as biochemical recurrence with PSA value greater than or equal to 0.2 ng/ml. Protein (from TMA), deletion, or RNA expression status was used to derive Kaplan-Meier curves on the subset of primary tumors that had clinical data on recurrence. A z-score threshold of 1.5 standard deviations was used to separate low (≤ -1.5) or high (≥ 1.5) from normal expression. For analysis of protein status, PTEN and PHLPP1 immunohistochemistry was performed on 21 22 a prostate cancer tumor tissue microarray with 114 evaluable cases in triplicate including normal tissue controls. PTEN and PHLPP1 staining was scored for each case as 0, +1, +2 by two reviewers. PTEN and PHLPP1 staining was considered negative with scores of 0 and 0/+1, respectively. All analyses for this publication were performed on de-identified patient data and material and thus qualified for exemption from human subjects statements under 45 CFR 46.101 (b) (4).
Statistical analysis of human metastasis data
For unbiased determination of significant co-deletions in metastatic samples mutual information was calculated for every pair of genes that was deleted at least 10 times (out of 37 samples) giving a total of >3000 genes (approximately 5 Mio pairs). Figure S5D ) difference in deletion frequency between the two groups. Areas of the genome with a statistically high frequency of aberration (indicated p value) were identified using the global frequency statistic approach of the STAC (Significance Testing for Aberrant Copy number) method (Diskin SJ et. al. Genome Res. 2006 16: 1149 -1158 and the results were plotted using the Circos application (Krzywinski M et al., Genome Res. 2009 Sep; 19(9) :1639-45).
